Satellos Bioscience Inc. (TSX:MSCL)
Canada
· Delayed Price · Currency is CAD 10.41
+0.57 (5.79%)
Apr 28, 2026, 3:59 PM EST
Satellos Bioscience Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Cash & Equivalents | 9.8 | 40.07 | 16.71 | 1.42 | 3.85 | Upgrade
|
| Short-Term Investments | 17.91 | 8.48 | 13.27 | - | - | Upgrade
|
| Cash & Short-Term Investments | 27.71 | 48.55 | 29.98 | 1.42 | 3.85 | Upgrade
|
| Cash Growth | -42.92% | 61.96% | 2008.62% | -63.07% | 583.57% | Upgrade
|
| Other Receivables | 0.37 | 0.44 | 0.44 | 0.19 | 0.42 | Upgrade
|
| Receivables | 0.37 | 0.44 | 0.44 | 0.19 | 0.42 | Upgrade
|
| Prepaid Expenses | 0.19 | 0.18 | 0.11 | 0.03 | 0.03 | Upgrade
|
| Other Current Assets | 3.62 | 1.58 | 0 | 0 | - | Upgrade
|
| Total Current Assets | 31.88 | 50.74 | 30.53 | 1.65 | 4.3 | Upgrade
|
| Property, Plant & Equipment | 0.01 | 0 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Long-Term Investments | - | - | 0.03 | 0.03 | - | Upgrade
|
| Other Intangible Assets | - | - | 2.97 | 2.89 | 5.64 | Upgrade
|
| Total Assets | 31.89 | 50.75 | 33.54 | 4.58 | 9.95 | Upgrade
|
| Accounts Payable | 1.77 | 2.06 | 0.79 | 1.08 | 0.89 | Upgrade
|
| Accrued Expenses | - | - | 1.96 | 1.01 | 0.77 | Upgrade
|
| Current Income Taxes Payable | 0.07 | - | - | - | - | Upgrade
|
| Other Current Liabilities | 2.26 | 1.52 | - | - | - | Upgrade
|
| Total Current Liabilities | 4.11 | 3.58 | 2.74 | 2.09 | 1.66 | Upgrade
|
| Total Liabilities | 4.11 | 3.58 | 2.74 | 2.09 | 1.66 | Upgrade
|
| Common Stock | 85.83 | 78.13 | 46.88 | 22.32 | 22.38 | Upgrade
|
| Additional Paid-In Capital | 10.17 | 7.9 | 6.44 | 2.72 | 0.98 | Upgrade
|
| Retained Earnings | -81.97 | -57.1 | -35.97 | -23.36 | -16.03 | Upgrade
|
| Comprehensive Income & Other | 13.76 | 18.23 | 13.45 | 0.8 | 0.97 | Upgrade
|
| Shareholders' Equity | 27.78 | 47.16 | 30.8 | 2.49 | 8.28 | Upgrade
|
| Total Liabilities & Equity | 31.89 | 50.75 | 33.54 | 4.58 | 9.95 | Upgrade
|
| Net Cash (Debt) | 27.71 | 48.55 | 29.98 | 1.42 | 3.85 | Upgrade
|
| Net Cash Growth | -42.92% | 61.96% | 2008.62% | -63.07% | - | Upgrade
|
| Net Cash Per Share | 1.90 | 5.08 | 4.16 | 0.48 | 1.92 | Upgrade
|
| Filing Date Shares Outstanding | 20.83 | 13.82 | 9.4 | 3.48 | 2.75 | Upgrade
|
| Total Common Shares Outstanding | 15.46 | 13.82 | 9.4 | 3.48 | 2.75 | Upgrade
|
| Working Capital | 27.78 | 47.16 | 27.79 | -0.44 | 2.64 | Upgrade
|
| Book Value Per Share | 1.80 | 3.41 | 3.28 | 0.71 | 3.01 | Upgrade
|
| Tangible Book Value | 27.78 | 47.16 | 27.83 | -0.4 | 2.64 | Upgrade
|
| Tangible Book Value Per Share | 1.80 | 3.41 | 2.96 | -0.12 | 0.96 | Upgrade
|
| Machinery | - | - | - | 0.01 | 0.01 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.